Answers are grounded in this paper and cite their sources.
A “basket study” testing a drug in patients whose tumor, in any tissue, has a specific mutation is a useful first research step. Next steps could be anatomic-site–specific trials comparing drug–mutation combinations with standard care and registries of off-label use.
No takes yet. Share an insight, caveat, or question.
Hunter et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: